Biopharmaceuticals
Regulatory
News Release - September 15, 2011
Astellas and Theravance Announce European Marketing Authorization for VIBATIV(R) for Nosocomial Pneumonia Caused by MRSA
Source: Theravance
Issuer of this News Release is solely responsible for its
content.
Please address inquiries directly to the issuing company.